Troubled by deaths, FDA orders Merck to slam the brakes on three Keytruda studies
A month after Merck flagged a higher risk of death in two combo studies using its flagship drug Keytruda, the FDA has followed up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
